Albert Liao1,2, Terry Hsieh1,3, Jasmine H Francis1,4, Jessica A Lavery5, Audrey Mauguen5, Scott E Brodie6, David H Abramson1,4. 1. Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York. 2. Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia. 3. Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, California. 4. Department of Ophthalmology, Weill-Cornell Medical Center, New York, New York. 5. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York; and. 6. Department of Ophthalmology, NYU Langone Health, New York, New York.
Abstract
PURPOSE: To compare retinal toxicity as measured by electroretinogram, ocular, and patient survival in retinoblastoma treated with intravitreal melphalan at two concentrations (25 vs. 30 µg). METHODS: Single-center, retrospective analysis of retinoblastoma eyes receiving 25-µg or 30-µg intravitreal melphalan from September 2012 to January 2019. Ocular toxicity was measured by electroretinogram of evaluable injections in 449 injections in 136 eyes. A repeated-measures linear mixed model with a random intercept and slope was applied to account for repeated measures for each eye. RESULTS: Average decline in electroretinogram after each additional injection was -4.9 µV (95% confidence interval -6.3 to -3.4); electroretinogram declined by -4.6 µV (95% confidence interval -7.0 to -2.2) after 25-µg injections and -5.2 µV (95% confidence interval -6.6 to -3.8) after 30-µg injections (P = 0.66). Injection at a new clock site hour was associated with a -3.91-µV lower average (95% confidence interval -7.8 to -0.04). CONCLUSION: Electroretinogram-measured toxicity in retinoblastoma eyes treated with intravitreal injections was not found to be different across 25-µg and 30-µg injections. There were no cases of extraocular extension or metastatic deaths in our patient population.
PURPOSE: To compare retinal toxicity as measured by electroretinogram, ocular, and patient survival in retinoblastoma treated with intravitreal melphalan at two concentrations (25 vs. 30 µg). METHODS: Single-center, retrospective analysis of retinoblastoma eyes receiving 25-µg or 30-µg intravitreal melphalan from September 2012 to January 2019. Ocular toxicity was measured by electroretinogram of evaluable injections in 449 injections in 136 eyes. A repeated-measures linear mixed model with a random intercept and slope was applied to account for repeated measures for each eye. RESULTS: Average decline in electroretinogram after each additional injection was -4.9 µV (95% confidence interval -6.3 to -3.4); electroretinogram declined by -4.6 µV (95% confidence interval -7.0 to -2.2) after 25-µg injections and -5.2 µV (95% confidence interval -6.6 to -3.8) after 30-µg injections (P = 0.66). Injection at a new clock site hour was associated with a -3.91-µV lower average (95% confidence interval -7.8 to -0.04). CONCLUSION: Electroretinogram-measured toxicity in retinoblastoma eyes treated with intravitreal injections was not found to be different across 25-µg and 30-µg injections. There were no cases of extraocular extension or metastatic deaths in our patient population.
Authors: Jasmine H Francis; Scott E Brodie; Brian Marr; Emily C Zabor; Ijah Mondesire-Crump; David H Abramson Journal: Ophthalmology Date: 2017-01-12 Impact factor: 12.079
Authors: Scott E Brodie; Yannis M Paulus; Mrinali Patel; Y Pierre Gobin; Ira J Dunkel; Brian P Marr; David H Abramson Journal: Br J Ophthalmol Date: 2012-03-18 Impact factor: 4.638
Authors: Jasmine H Francis; David H Abramson; Xunda Ji; Carol L Shields; Luiz F Teixeira; Amy C Schefler; Nathalie Cassoux; Doris Hadjistilianou; Jesse L Berry; Shahar Frenkel; Francis L Munier Journal: JAMA Ophthalmol Date: 2017-12-01 Impact factor: 7.389
Authors: Jasmine H Francis; David H Abramson; Marie-Claire Gaillard; Brian P Marr; Maja Beck-Popovic; Francis L Munier Journal: Ophthalmology Date: 2015-03-18 Impact factor: 12.079
Authors: Jesse L Berry; Sona Shah; Mercy Bechtold; Emily Zolfaghari; Rima Jubran; Jonathan W Kim Journal: Pediatr Blood Cancer Date: 2017-06-24 Impact factor: 3.167
Authors: Carley M Bogan; Janene M Pierce; Stephanie D Doss; Yuankai K Tao; Sheau-Chiann Chen; Kelli L Boyd; Albert Liao; Terry Hsieh; David H Abramson; Jasmine H Francis; Debra L Friedman; Ann Richmond; Anthony B Daniels Journal: Exp Eye Res Date: 2021-01-11 Impact factor: 3.467
Authors: Paula Schaiquevich; Jasmine H Francis; María Belén Cancela; Angel Montero Carcaboso; Guillermo L Chantada; David H Abramson Journal: Front Oncol Date: 2022-04-01 Impact factor: 5.738
Authors: Carley M Bogan; Jessica V Kaczmarek; Janene M Pierce; Sheau-Chiann Chen; Kelli L Boyd; Marion W Calcutt; Thomas M Bridges; Craig W Lindsley; Jennifer B Nadelmann; Albert Liao; Terry Hsieh; David H Abramson; Jasmine H Francis; Debra L Friedman; Ann Richmond; Anthony B Daniels Journal: Br J Ophthalmol Date: 2021-05-10 Impact factor: 4.638